The effect of obesity on outcome of unrelated cord blood transplant in children with malignant diseases. Bone Marrow Transplant

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pediatric Stem Cell Transplant Program, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.
Bone marrow transplantation (Impact Factor: 3.57). 12/2010; 46(10):1309-13. DOI: 10.1038/bmt.2010.312
Source: PubMed


Obesity has become a pandemic, affecting both children and adults. We sought to determine the effect of obesity among 200 children who were prospectively enrolled on a multicenter cord blood transplant (CBT) trial. All patients received myeloablative preparative regimens. Children were classified into groups according to body mass index percentile. Normal weight was defined as body mass index between the 5th and 85th percentile (n=117), overweight between the 85th and 95th percentile (n=35) and obesity above 95th percentile (n=39) for age and gender. A total of 55 patients (27%) had AML, 113 patients (57%) had ALL and 32 patients (16%) had other malignant diseases. There was no evidence for a difference in all major characteristics among the groups. Time to neutrophil and platelet engraftment, TRM, risk of acute GVHD, disease-free survival and OS were not significantly different in overweight or obese patients compared with normal weight patients. There was a trend towards increased risk of chronic GVHD in obese patients (P=0.05) compared with normal weight patients. In conclusion, there is insufficient evidence from this sample that obesity has an effect on multiple outcomes after unrelated CBT in children with malignant diseases.

Download full-text


Available from: Frank E Harrell, Mar 31, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic cell transplantation (HCT) is a high-risk procedure of curative potential for patients with various malignant and nonmalignant hematological diseases. Because the procedure carries considerable risks of treatment-related morbidity and mortality and has variable results in improving disease-free survival, patient selection plays an important role in its success. One patient factor that has received attention in the last 20 years has been the concern that obese patients may not have outcomes similar to normal weight individuals because of (1) altered pharmacokinetics of commonly used chemotherapeutic agents [1, 2], (2) presence of other medical comorbidities with obesity [3], and (3) higher morbidity associated with obesity itself [4], which may result in higher post-HCT morbidity/mortality. Because obesity has become a pandemic affecting both children and adults in the United States and worldwide [5–8], the body of literature evaluating the relationship between obesity and clinical outcomes in the setting of HCT has grown as well. This chapter explores the pharmacokinetics, pharmacodynamics, and clinical outcomes of HCT in the setting of obesity.
    Energy Balance and Hematologic Malignancies, 01/2012: pages 129-140; , ISBN: 978-1-4614-2402-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IMPORTANCE Obesity is prevalent among hospitalized children. Knowledge of the relationship between obesity and outcomes in hospitalized children will enhance nutrition assessment and provide opportunities for interventions. OBJECTIVE To systematically review the existing literature concerning the impact of obesity on clinical outcomes in hospitalized children. EVIDENCE ACQUISITION PubMed, Web of Science, and EMBASE databases were searched for studies of hospitalized children aged 2 to 18 years with identified obesity and at least 1 of the following clinical outcomes: all-cause mortality, incidence of infections, and length of hospital stay. Cohort and case-control studies were included. Cross-sectional studies, studies of healthy children, and those without defined criteria for classifying weight status were excluded. The Newcastle-Ottawa Scale was used to assess study quality. RESULTS Twenty-eight studies (26 retrospective; 24 cohort and 4 case-control) were included. Of the 21 studies that included mortality as an outcome, 10 reported a significant positive relationship between obesity and mortality. The incidence of infections was assessed in 8 of the 28 studies; 2 reported significantly more infections in obese compared with nonobese patients. Of the 11 studies that examined length of stay, 5 reported significantly longer lengths of hospital stay for obese children. Fifteen studies (53%) had a high quality score. Larger studies observed significant relationships between obesity and outcomes. Studies of critically ill, oncologic or stem cell transplant, and solid organ transplant patients showed a relationship between obesity and mortality. CONCLUSIONS AND RELEVANCE The available literature on the relationship between obesity and clinical outcomes is limited by subject heterogeneity, variations in criteria for defining obesity, and outcomes examined. Childhood obesity may be a risk factor for higher mortality in hospitalized children with critical illness, oncologic diagnoses, or transplants. Further examination of the relationship between obesity and clinical outcomes in this subgroup of hospitalized children is needed.
    03/2013; 167(5):1-7. DOI:10.1001/jamapediatrics.2013.13
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The impact of being overweight on outcome after hematopoietic SCT (HSCT) is controversial. We performed meta-analyses to evaluate the impact of being overweight on acute graft-versus-host disease (aGVHD) risk and survival. Original data were obtained from MEDLINE, and studies that evaluated being overweight before transplantation in recipients as a risk factor for aGVHD or a prognostic factor for overall survival (OS) were extracted. Study-specific relative risks on the log scale comparing overweight with non-overweight patients were used to obtain a pooled RR with 95% confidence interval (CI). We identified 8 studies of aGVHD and 21 of OS. In allogeneic HSCT, the meta-analysis determined statistically significant associations of overweight recipients with aGVHD risk and OS. Meta-analysis of the 8 studies of aGVHD indicated that the RR for overweight to non-overweight patients was 1.186 (95% CI: 1.072-1.312). Regarding OS, meta-analysis of 11 allogeneic HSCT studies indicated that the RR for overweight to non-overweight patients was 1.163 (1.009-1.340). Our results indicate that being overweight before transplantation in recipients is associated with a high aGVHD rate and worse survival after allogeneic HSCT. Potential heterogeneity especially in adult/pediatric patients limits the interpretability of our finding. Further, well-designed large cohort studies are warranted.Bone Marrow Transplantation advance online publication, 19 August 2013;. doi:10.1038/bmt.2013.128.
    Bone marrow transplantation 08/2013; 49(1). DOI:10.1038/bmt.2013.128 · 3.57 Impact Factor
Show more